Exabis Library
Welcome to the e-CCO Library!
P551: Use of preoperative total parenteral nutrition is associated with clinical and laboratory remission in severe active Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P552 Withdrawal of immunomodulator medications (IM) in children with inflammatory bowel disease on combination therapy of IM and biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P552: An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P552: Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P552: Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P552: Gastroenterologists’ perceptions on use of medical cannabis for IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P552: Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P553 Safety of the sequential use of biological therapy in inflammatory bowel disease: Results from a tertiary referral centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P553: Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P554 Dietary practices and beliefs of patients with inactive ulcerative colitis: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P554: Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM